Clinical

Dataset Information

0

Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC


ABSTRACT: The purpose of this study is to assess the objective response rate (ORR) when panitumumab is administered in combination with irinotecan as 2nd-line therapy in subjects with previously treated metastatic colorectal cancer (mCRC).

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2040127 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
| 2624715 | ecrin-mdr-crc
| PRJNA989347 | ENA
2010-05-06 | GSE12191 | GEO
2018-11-21 | GSE110785 | GEO
2013-12-01 | GSE52735 | GEO
2013-11-20 | GSE52513 | GEO
| 2624716 | ecrin-mdr-crc
2010-06-04 | PRD000201 | Pride
2024-11-12 | GSE281374 | GEO